Contribute Try STAT+ Today

In a big win for the Federal Trade Commission, a federal judge ordered AbbVie (ABBV) and another company to pay $448 million to consumers for violating antitrust laws and striking deals that delayed lower-cost generic versions of their AndroGel testosterone treatment from reaching the market.

The Friday decision comes in response to a lawsuit the FTC filed nearly four years ago in which AbbVie was accused of filing “sham” patent litigation against potential generic rivals, and then entered into an allegedly illegal patent settlement in order to thwart competition.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy